

Raul Mendez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/622577/raul-mendez-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

707
citations

16
h-index

26
g-index

50
ext. papers

1,062
ext. citations

5
avg. IF

4.12
L-index

#	Paper	IF	Citations
43	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1287-1297	10.2	103
42	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. <i>Critical Care</i> , 2020 , 24, 691	10.8	99
41	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62
40	Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. <i>Journal of Internal Medicine</i> , 2021 , 290, 621-631	10.8	52
39	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44
38	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017 , 24, 231-236	8.8	43
37	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019 , 78, 423-431	18.9	28
36	Lung inflammatory pattern and antibiotic treatment in pneumonia. <i>Respiratory Research</i> , 2015 , 16, 15	7.3	24
35	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 370-378	10.2	23
34	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019 , 156, 1080-1091	5.3	21
33	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017 , 18, 176	7.3	19
32	Reduced Diffusion Capacity in COVID-19 Survivors. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1253-1255	4.7	18
31	C-Reactive Protein at Discharge, Diabetes Mellitus and \square Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 306-14	2	17
30	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017 , 17, 659	4	17
29	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
28	Age-related risk factors for bacterial aetiology in community-acquired pneumonia. <i>Respirology</i> , 2016 , 21, 1472-1479	3.6	16
27	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. <i>Haematologica</i> , 2021 , 106, 1636-1646	6.6	15

26	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 1-10	0.7	11
25	Simultaneous Depression of Immunological Synapse and Endothelial Injury is Associated with Organ Dysfunction in Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
24	Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
23	Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
22	Long-term neuropsychiatric outcomes in COVID-19 survivors: A 1-year longitudinal study. <i>Journal of Internal Medicine</i> , 2021 ,	10.8	7
21	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. <i>Archivos De Bronconeumología</i> , 2020 , 56, 551-558	0.7	5
20	ESICM LIVES 2016: part one. <i>Intensive Care Medicine Experimental</i> , 2016 , 4,	3.7	5
19	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2021 ,	1.6	5
18	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
17	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
16	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
15	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1087-1097	4.7	3
14	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5.8	3
13	Soluble P-Selectin in Acute Exacerbations and Stable Bronchiectasis in Adults. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1587-1591	4.7	2
12	Non-cystic fibrosis bronchiectasis: The long road to multidrug resistant bacteria. <i>Community Acquired Infection</i> , 2016 , 3, 110	0	2
11	Factors associated with one-year mortality in hospitalised patients with exacerbated bronchiectasis. <i>Archivos De Bronconeumología</i> , 2022 ,	0.7	2
10	Short-term Neuropsychiatric Outcomes and Quality of Life in COVID-19 Survivors		1
9	Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. <i>Archivos De Bronconeumología</i> , 2020 , 56, 551-558	0.7	1

8	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
7	Ceftobiprole medocaril.. <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 25-27	1.6	0
6	Reply to Dual antibiotic therapy for outpatient management of community-acquired pneumonia? <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
5	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
4	Solithromycin: the future of macrolide is now. <i>Annals of Research Hospitals</i> , 2017 , 1, 1-1	1.6	
3	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 41, 271	5.3	
2	Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections 2020 , 212-228		
1	Bronchiectasis and Multidrug-resistant Microorganisms: The Ideal Niche?. <i>Archivos De Bronconeumologia</i> , 2018 , 54, 543-544	0.7	